Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
Alisa B. Lee‐Sherick, Kristen M. Jacobsen, Curtis J. Henry, et al.
JCI Insight (2018) Vol. 3, Iss. 21
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 46
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti–PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer
Canan Kasikara, Viralkumar Davra, David Calianese, et al.
Cancer Research (2019) Vol. 79, Iss. 10, pp. 2669-2683
Closed Access | Times Cited: 94
TAM receptors, Phosphatidylserine, inflammation, and Cancer
Tal Burstyn‐Cohen, Avi Maimon
Cell Communication and Signaling (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 83
<p>Progression of the role of CRYAB in signaling pathways and cancers</p>
Jun-Fei Zhang, Jia Liu, Jiali Wu, et al.
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 4129-4139
Open Access | Times Cited: 80
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Justus M. Huelse, Diana Fridlyand, Shelton Earp, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107577-107577
Open Access | Times Cited: 71
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
January Salas-McKee, Weimin Kong, Whitney L. Gladney, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 5, pp. 1126-1132
Open Access | Times Cited: 61
TAM Receptor Inhibition–Implications for Cancer and the Immune System
Pia Aehnlich, Richard Powell, Marlies J. W. Peeters, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1195-1195
Open Access | Times Cited: 55
Tissue-specific modifier alleles determine Mertk loss-of-function traits
Yemsratch T. Akalu, María E. Mercau, Marleen Ansems, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 35
Therapeutic targeting of the functionally elusive TAM receptor family
Yu Rebecca Miao, Erinn B. Rankin, Amato J. Giaccia
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 3, pp. 201-217
Open Access | Times Cited: 19
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
Elena Tondini, Tsolère Arakelian, Koen Oosterhuis, et al.
OncoImmunology (2019) Vol. 8, Iss. 11, pp. 1652539-1652539
Open Access | Times Cited: 52
Production, characterization, andin vivohalf-life extension of polymeric IgA molecules in mice
T. Noelle Lombana, Sharmila Rajan, Julie A. Zorn, et al.
mAbs (2019) Vol. 11, Iss. 6, pp. 1122-1138
Open Access | Times Cited: 49
MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
Marlies J. W. Peeters, Donata Dulkeviciute, Arianna Draghi, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 9, pp. 1472-1484
Open Access | Times Cited: 47
Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment
Joselyn Cruz Cruz, Kristen C. Allison, Lauren S. Page, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Phosphatidylserine externalization as immune checkpoint in cancer
Ivan-Maximilano Kur, Andreas Weigert
Pflügers Archiv - European Journal of Physiology (2024)
Open Access | Times Cited: 5
TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
Marlies J. W. Peeters, Anne Rahbech, Per thor Straten
Cancer Immunology Immunotherapy (2019) Vol. 69, Iss. 2, pp. 237-244
Open Access | Times Cited: 37
Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis
Benjamin Meir Jacobs, Thomas R. Taylor, Amine Awad, et al.
Brain Communications (2020) Vol. 2, Iss. 2
Open Access | Times Cited: 33
Mertk: An emerging target in cancer biology and immuno-oncology
Kevin C. Lahey, Varsha Gadiyar, Amanda A. Hill, et al.
International review of cell and molecular biology (2022), pp. 35-59
Open Access | Times Cited: 22
Progress of research on PD-1/PD-L1 in leukemia
Huizhen Cao, Tianyu Wu, Xue Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Diana Llópiz, Leyre Silva, Marta Ruiz, et al.
OncoImmunology (2025) Vol. 14, Iss. 1
Open Access
Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?
Ivana Malíková, Anastassiya Vetrova, Diana Aliyeva, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Clonal hematopoiesis of indeterminate potential: contribution to disease and promising interventions
Chongjie Li, Chunxiang Zhang, Xiuying Li
Molecular and Cellular Biochemistry (2025)
Open Access
Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Miso Park, Keon Wook Kang
Archives of Pharmacal Research (2019) Vol. 42, Iss. 7, pp. 617-628
Closed Access | Times Cited: 32
Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine
Sonia Bianchini, Ciriana Orabona, Barbara Camilloni, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 16, Iss. 1, pp. 86-94
Open Access | Times Cited: 30
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Dan Yan, H. Shelton Earp, Deborah DeRyckere, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5639-5639
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top